Thiotepa: alkylating agent for chemotherapy

Tepadina (thiotepa) is a cytotoxic treatment for haematological disease and solid tumours. It is approved for use alongside other forms of chemotherapy in preparation for allogeneic or autologous haematopoietic progenitor cell transplantation.

Thiotepa acts as an alkylating agent. It has efficacy in a variety of malignancies, including lymphoma and myeloma, breast and ovarian cancer and tumours of the central nervous system and germ cells. Treatment must be supervised by a specialist.

View Tepadina drug record

Further information: Intrapharm

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases